These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Telomeres and telomerase in Sarcoma disease and therapy. Huang J; Feng Y; Shi Y; Shao W; Li G; Chen G; Li Y; Yang Z; Yao Z Int J Med Sci; 2024; 21(11):2065-2080. PubMed ID: 39239547 [TBL] [Abstract][Full Text] [Related]
24. Sarcomas of the skin in the elderly. Mentzel T Clin Dermatol; 2011; 29(1):80-90. PubMed ID: 21146736 [TBL] [Abstract][Full Text] [Related]
25. Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotype. Koelsche C; Stichel D; Griewank KG; Schrimpf D; Reuss DE; Bewerunge-Hudler M; Vokuhl C; Dinjens WNM; Petersen I; Mittelbronn M; Cuevas-Bourdier A; Buslei R; Pfister SM; Flucke U; Mechtersheimer G; Mentzel T; von Deimling A Clin Sarcoma Res; 2019; 9():2. PubMed ID: 30809375 [TBL] [Abstract][Full Text] [Related]
26. TERT and TERT promoter in melanocytic neoplasms: Current concepts in pathogenesis, diagnosis, and prognosis. Motaparthi K; Kim J; Andea AA; Missall TA; Novoa RA; Vidal CI; Fung MA; Emanuel PO J Cutan Pathol; 2020 Aug; 47(8):710-719. PubMed ID: 32202662 [TBL] [Abstract][Full Text] [Related]
27. POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families. Potrony M; Puig-Butille JA; Ribera-Sola M; Iyer V; Robles-Espinoza CD; Aguilera P; Carrera C; Malvehy J; Badenas C; Landi MT; Adams DJ; Puig S Br J Dermatol; 2019 Jul; 181(1):105-113. PubMed ID: 30451293 [TBL] [Abstract][Full Text] [Related]
28. TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. Lee S; Barnhill RL; Dummer R; Dalton J; Wu J; Pappo A; Bahrami A Sci Rep; 2015 Jun; 5():11200. PubMed ID: 26061100 [TBL] [Abstract][Full Text] [Related]
29. TERT promoter mutations in periocular carcinomas: implications of ultraviolet light in pathogenesis. Lin SY; Liao SL; Hong JB; Chu CY; Sheen YS; Jhuang JY; Tsai JH; Liau JY Br J Ophthalmol; 2016 Feb; 100(2):274-7. PubMed ID: 26472403 [TBL] [Abstract][Full Text] [Related]
30. TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Griewank KG; Murali R; Schilling B; Scholz S; Sucker A; Song M; Süsskind D; Grabellus F; Zimmer L; Hillen U; Steuhl KP; Schadendorf D; Westekemper H; Zeschnigk M Br J Cancer; 2013 Jul; 109(2):497-501. PubMed ID: 23799844 [TBL] [Abstract][Full Text] [Related]
31. Increase of atypical fibroxanthoma and pleomorphic dermal sarcoma: a retrospective analysis of four German skin cancer centers. Kuntz T; Siebdrath J; Hofmann SC; Baltaci M; Schaller J; Hellmich M; von Goltzheim LS; Assaf C; Oellig F; Michalowitz AL; Helbig D; Kreuter A J Dtsch Dermatol Ges; 2022 Dec; 20(12):1581-1588. PubMed ID: 36442137 [TBL] [Abstract][Full Text] [Related]
32. TERT promoter mutations and gene amplification: promoting TERT expression in Merkel cell carcinoma. Xie H; Liu T; Wang N; Björnhagen V; Höög A; Larsson C; Lui WO; Xu D Oncotarget; 2014 Oct; 5(20):10048-57. PubMed ID: 25301727 [TBL] [Abstract][Full Text] [Related]
33. Classifying Melanoma by TERT Promoter Mutational Status. Shaughnessy M; Njauw CN; Artomov M; Tsao H J Invest Dermatol; 2020 Feb; 140(2):390-394.e1. PubMed ID: 31425705 [TBL] [Abstract][Full Text] [Related]